Our systematic review and meta-analysis demonstrated that osteocalcin, procollagen type I N-terminal propeptide, and collagen type I cross-linked C-telopeptide in patients with NAFLD have significantly lower levels than the control group. The gene discussed is COL1A2; the disease is metabolic dysfunction-associated steatotic liver disease.